ReviewInternational journal of clinical practice2008
Is adiposopathy (sick fat) an endocrine disease?
Review in International journal of clinical practice, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Trial
- Lifestyle-induced decrease in fat mass improves adiponectin secretion in obese adults.Medicine and science in sports and exercise · 2014Trial
- The Potential Benefits of a Novel Food Supplement Based on Cannabis Sativa, Boswellia, and Fish Oil for Pain and Inflammation in Physical Activity: Unraveling the Role of Orexin-A Modulation.Sports (Basel, Switzerland) · 2025Article
- Association between metabolic score for visceral fat and chronic pain: a cross-sectional analysis of NHANES 1999-2004.Frontiers in nutrition · 2025Article
- The energy model of insulin resistance: A unifying theory linking seed oils to metabolic disease and cancer.Frontiers in nutrition · 2025Article
- Machine learning prediction of metabolic dysfunction-associated fatty liver disease risk in American adults using body composition: explainable analysis based on SHapley Additive exPlanations.Frontiers in nutrition · 2025Article
- Obesity management in primary care: Are we adequately preparing the next generation of Canadian family physicians?Obesity pillars · 2024Article
- Awareness is not enough: Developing competencies in behaviour change counselling for obesity management.Obesity pillars · 2024Article
- Fasting hyperglycaemia and fatty liver drive colorectal cancer: a retrospective analysis in 1145 patients.Internal and emergency medicine · 2024Article
- Article
- Helping providers address psychological aspects of obesity in routine care: Development of the obesity adjustment dialogue tool (OADT).Obesity pillars · 2023Article
- Contribution of markers of adiposopathy and adipose cell size in predicting insulin resistance in women of varying age and adiposity.Adipocyte · 2022Article
- Managing weight and glycaemic targets in people with type 2 diabetes-How far have we come?Endocrinology, diabetes & metabolism · 2022Review
- Assessment, differential diagnosis, and initial clinical evaluation of the pediatric patient with obesity: An Obesity Medical Association (OMA) Clinical Practice Statement 2022.Obesity pillars · 2022Article
- Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.Obesity pillars · 2022Article
- Review
- Article
- The Interplay between Angiopoietin-Like Proteins and Adipose Tissue: Another Piece of the Relationship between Adiposopathy and Cardiometabolic Diseases?International journal of molecular sciences · 2021Review
- Comparing an adiposopathy approach with four popular classifications schemes to categorize the metabolic profile of postmenopausal women.Journal of physiology and biochemistry · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review current consensus and controversy regarding whether obesity is a 'disease', examine the pathogenic potential of adipose tissue to promote metabolic disease and explore the merits of 'adiposopathy' and 'sick fat' as scientifically and clinically useful terms in defining when excessive body fat may represent a 'disease'.
methodsA group of clinicians and researchers, all with a background in endocrinology, assembled to evaluate the medical literature, as it pertains to the pathologic and pathogenic potential of adipose tissue, with an emphasis on metabolic diseases that are often promoted by excessive body weight.
resultsThe data support pathogenic adipose tissue as a disease. Challenges exist to convince many clinicians, patients, healthcare entities and the public that excessive body fat is often no less a 'disease' than the pathophysiological consequences related to anatomical abnormalities of other body tissues. 'Adiposopathy' has the potential to scientifically define adipose tissue anatomic and physiologic abnormalities, and their adverse consequences to patient health. Adiposopathy acknowledges that when positive caloric balance leads to adipocyte hypertrophy and visceral adiposity, then this may lead to pathogenic adipose tissue metabolic and immune responses that promote metabolic disease. From a patient perspective, explaining how excessive caloric intake might cause fat to become 'sick' also helps provide a rationale for patients to avoid weight gain. Adiposopathy also better justifies recommendations of weight loss as an effective therapeutic modality to improve metabolic disease in overweight and obese patients.
conclusionAdiposopathy (sick fat) is an endocrine disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.